An observational study in Sarcoma and Melanoma, sponsored by National Cancer Centre, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by National Cancer Centre, Singapore · Observational
This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.
Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.
Hypothesis: Ex vivo drug testing on patient-derived models using QPOP can identify drug sensitivities and combinations which may have clinical efficacy against sarcomas and melanomas.
Specific aim 1: To derive patient models, both two- and three-dimensional, of sarcomas and melanomas
Specific aim 2: To perform ex vivo drug testing on patient models of sarcoma and melanoma using QPOP
Specific aim 3: To assess the efficacy of phenotype directed therapy using QPOP to assign treatment after progression on standard-of-care treatment in sarcoma and melanoma
1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.
This study's planned enrollment of 100 is below the median of 121 across 238 observational studies indexed under Sarcoma.
Browse Sarcoma studies →National Cancer Centre, Singapore is the lead sponsor of 116 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient aged between 21 to 99 diagnosed with sarcoma or melanoma.
Exclusion Criteria:
Percentage of patients with successful model generation for each tumour subtype.
Patients enrolled on study will undergo resection or biopsy of fresh tumour tissue to obtain cells for the generation of models.
Time frame: 8 years.
Rates of radiological response from QPOP-directed treatment regimens.
Complete and partial clinical response and stable disease.
Time frame: 8 years.
Survival outcomes from QPOP-directed treatment regimens.
Overall survival, progression-free survival.
Time frame: 8 years.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Centre, Singapore